# Isto Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/isto-technologies

- Industry: Medical Devices & Equipment
- Headquarters: St. Louis, US
- Website: www.istotech.com/
- Total disclosed funding: $13M
- Latest round: Series E (Jun 1, 2009)
- Investors on record: 4

## About

Based in the United States, ISTO Technologies, Inc. operates as a B2B orthobiologics developer. The company provides biologic products for orthopedic and spinal applications, bone graft extenders and substitutes, cell-based therapies for degenerative disc disease, and regenerative cartilage implants for knee repair. Based in Missouri, United States and founded in 1997, ISTO Technologies, Inc. provides orthobiologic solutions for the orthopedic and spinal care industry. The company focuses on developing biologic products aimed at cartilage regeneration, spinal therapy, sports medicine, and trauma treatment. ISTO pioneered patented juvenile cell technology, which offers superior regenerative potential compared to adult cells, enabling breakthrough therapies for knee cartilage repair and degenerative disc disease. Over the years, ISTO has expanded its pipeline to include products such as InQu (bone graft extender), NuQu (cell-based therapy for spinal discs), and RevaFlex (living cartilage implant), positioning itself as an innovator in regenerative medicine. In October 2016, Isto Holdings., a portfolio company of Thompson Street Capital Partners, acquired Arteriocyte Medical Systems, Inc., a portfolio company of DW Healthcare Partners. As a part of the transaction, ISTO Technologies’ Commercial Business will be rebranded to ISTO Biologics. Following the transaction ISTO Technologies and Arteriocyte Medical Systems will operate under the name of ISTO Biologics. The company works with healthcare providers, orthopedic surgeons, and hospitals to provide advanced orthobiologic solutions. The company develops and supplies InQu, a hyaluronic acid-based bone graft extender and substitute designed to support bone formation; NuQu, a cell-based therapy in development for treating degenerative disc disease using juvenile cartilage cells; and RevaFlex, a scaffold-free living cartilage implant aimed at repairing and regenerating knee cartilage.

## Funding rounds

- Series E, Jun 1, 2009, $8.8M — EQT Life Sciences, Alafi Capital, Ascension Ventures, Mid-America Transplant Services
- Series E, Mar 13, 2007, $4.2M — Alafi Capital

## Investors

- Alafi Capital (https://capitalatlas.ai/funds/alafi-capital) — Series E
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series E
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series E
- Mid-America Transplant Services — Series E